AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Kamada Ltd (KMDA) reaffirms 2025 financial outlook with total revenues projected between $178 million and $182 million, and adjusted EBITDA between $40 million and $44 million, indicating significant revenue and EBITDA growth. The company operates in the healthcare sector, focusing on plasma-derived protein therapeutics, with a robust product portfolio and strong financial health. Favorable valuation ratios and positive analyst sentiment further support Kamada's growth trajectory.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet